ClinicalTrials.gg
CompletedNCT06795204Updated Jan 13, 2026Results posted

Effects of HSK3486 on Cardiac Repolarization in Health Subjects (TQT)

A Phase 1 interventional study of HSK3486 and Moxifloxacin Hydrochloride in Anesthesia; Adverse Effect and Cardiac Arrhythmia, sponsored by Haisco-USA Pharmaceuticals, Inc.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Haisco-USA Pharmaceuticals, Inc. (part of Haisco Pharmaceutical Group Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Apr 2024, registered Jan 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies in Arrhythmias, Cardiac with a site in China — 21 open to participants now, 24 under way, none of them phase 3. Arrhythmias, Cardiac · China.

Enrollment
23rd of 27
48 · median 130
Started
2024
with 7 others
Phase 1
Only one
of the 46
Registered
32nd of 46
by date

Among the 46 studies in Arrhythmias, Cardiac with a site in China, this one is the 23rd largest by enrollment of the 27 interventional ones that give a count, is one of 8 that started in 2024, is the only one in phase 1, and was the 32nd registered.

Arrhythmias, Cardiac

1,051 studies on the registry are indexed under Arrhythmias, Cardiac; 236 are open to participants now.

Browse Arrhythmias, Cardiac studies →

Open to participants now

21 of the 46 studies in Arrhythmias, Cardiac with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 167 Arrhythmias, Cardiac studies recruiting now, 118 (71%) set no upper age limit and 13 (8%) stop at 75 or younger; 31 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Arrhythmias, Cardiac with a site in China, or all of them as a file.
02

Study summary

To assess the effects of a single IV bolus of HSK3486 single dose on cardiac repolarization (QTc interval of the electrocardiogram, and to evaluate the safety and tolerability of a single IV bolus of HSK3486 in healthy subjects

Read the detailed description

This is a single-center, randomized, blinded (except moxifloxacin hydrochloride tablet), placebo and positive controlled study with a 6-sequence, three-period crossover design in healthy subjects. A blinded design is used for administration of HSK3486 and placebo, and an open-label design is used for moxifloxacin hydrochloride tablet.

Subjects meet the including criteria and none of exclusion criteria are randomized in equal proportion to one of 6 dosing sequences (see Table 2 for dosing sequences), and the study procedure consisted of 3 periods, with washout period of 5 days between periods.

Subjects are closely monitored on vital sign checking, 12-lead ECG, and Holter collection through out each treatment period.

03

Conditions studied

  • Anesthesia; Adverse Effect
  • Cardiac Arrhythmia
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand and comply with protocol requirements and was voluntarily sign written form (ICF).
  2. Healthy participants at age from 18 to 45 years old (inclusive) at Screening.
  3. Male body weight ≥50 kg, female body weight ≥45 kg, with a BMI of 19\~28 kg/m2 (inclusive).
  4. (LVEF)≥50%.

Exclusion criteria

Exclusion Criteria:

  1. Past or present systemic disease as judged by the Investigator including, but not limited to psychiatric, neurologic, pulmonary, respiratory, cardiac, gastrointestinal, genitourinary, renal, hepatic, metabolic, endocrinologic, hematological, or disorders.
  2. History of allergy to egg or egg products, soybean or soy products.
  3. History of significant , intolerance, or allergy to any drug compound, food, or other substance. History of allergy to HSK3486 or moxifloxacin or its product , or history of specific allergies (asthma, urticaria, eczema, etc.), or history of tendinitis or tendon rupture due to moxifloxacin or any other quinolone drug.
  4. Clinically significant infection/injury/disease within 1 month prior to dosing.
  5. Current or recent (\< 6 months from screening) hepatobiliary disease.
  6. Current or history of seizure disorder, including alcohol- or stimulant-related seizure, febrile seizure, or significant family history of idiopathic seizure disorder.
  7. Family history of sudden death at \<50 years of age.
  8. History of unexplained loss of consciousness, unexplained syncope, unexplained irregular heartbeats or palpitations, clinically significant head injury.
  9. Pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function, or conditions that could interfere with the absorption, metabolism, and/or excretion of study drug (e.g., history of bariatric surgery or intestinal bypass surgery; simple uncomplicated appendectomies and hernia repairs are allowed, but cholecystectomy is not allowed).
  10. Positive test results for surface antigen, antibody, treponema pallidum antibody, (HIV) antigen/antibody combination test.
  11. Subjects with previous or suspected difficult airway (e.g., modified Mallampati score III- IV, congenital microglossia, mandibular dysplasia), or respiratory insufficiency, history of obstructive pulmonary disease, history of asthma, sleep apnea syndrome; history of failed tracheal intubation; history of bronchospasm requiring treatment within 3 months prior to screening; acute respiratory infection, and with obvious symptoms such as fever, wheezing, nasal congestion or cough within 1 week prior to baseline.
  12. Knowledge of any kind of cardiovascular disorder/condition/procedure known to increase the possibility of or history of risk factors for torsade de pointes (e.g., heart failure, hypokalemia, hypomagnesemia, congenital Long QT syndrome, or family history of Long QT Syndrome).
  13. Laboratory tests at screening or baseline judged clinically significant by the investigator, including, but not limited to, (ALT) or aspartate aminotransferase or aspartate aminotransferase (AST) > 1.2 × (ULN)(the upper limit of the reference range at screening or baseline), direct > ULN (congenital nonhemolytic hyperbilirubinemia [e.g., suspicion of Gilbert's syndrome based on total and direct bilirubin] is not acceptable), creatine kinase (CK) > ULN (one repeat test allowed), thyroid stimulating hormone (TSH) outside normal range (0.75 to 5.6 mIU/L) , serum potassium outside normal range (3.5 to 5.3 mmol/L).
  14. Rest sitting vital sign results abnormal and clinically significant at screening or baseline, ear temperature outside normal range, diastolic blood pressure ≥ 90 mmHg or systolic blood pressure ≥ 140 mmHg, heart rate (HR) \< 55 beats/min or > 100 beats/min (test can be repeated once according to investigator's judgment).
  15. Oxygen saturation (SpO2) below 95% at baseline.
  16. Abnormal 12-lead at screening or baseline (any test abnormality), including any of the following:

    1. QTcF > 450 ms
    2. QRS > 110 ms
    3. PR > 200 ms
    4. Second or third-degree AV block
    5. Any rhythm other than sinus rhythm of clinical significance.
  17. Estimated (eGFR) \< 90 mL/min (estimated using MDRD equation).
  18. Participation in another clinical study of an investigational drug (or medical device) within 3 months (or 5 half-lives, whichever is longer) prior to dosing, or previous participation in any other clinical trial related to HSK3486.
  19. Donation of blood within 3 months prior to screening, plasma within 2 weeks prior to screening, within 6 weeks prior to screening, or receive blood products within 2 months prior to admission to the investigational site.
  20. Sperm and egg donation program from screening period to 90 days after study end.
  21. Pregnant or lactating women or those with positive pregnancy test results. Male or female subjects of did not agree to use an effective method of from the time of signing ICF until 90 days after leaving the investigational site after the last dose (see Appendix 6 for details of specific contraceptive methods).
  22. Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to dosing or during the clinical trial.
  23. Use or intend to use of any prescription, nonprescription, vitamin, herbal, or nutraceutical within 14 days prior to dosing or during the clinical trial.
  24. Smoking (≥ 5 cigarettes per day) within 6 months prior to screening, or inability to quit smoking during the trial.
  25. Positive alcohol breath test, or regular drinking within 6 months prior to dosing or during the trial, i.e. drinking more than 21 units (men) or 14 units (women) of alcohol per week (1 unit =360 mL beer or 45 mL spirits or 150 mL wine at 40% alcohol).
  26. Positive urine drug abuse screening (morphine, tetrahydrocannabinol, methamphetamine, methylenedioxyamphetamine, ketamine), or history of drug abuse, drug dependence within 6 months prior to screening, or drug use within 3 months prior to screening.
  27. Subjects who tested positive for COVID-19 during screening.
  28. Eating fruits or foods affecting metabolic enzymes, such as grapefruit (citrus), pomelo, etc., within 7 days prior to screening; and not abstaining from the above beverages, fruits or foods during the study period.
  29. Previous chronic excessive consumption (more than 8 cups per day, 1 cup =250 mL) of tea, coffee or caffeinated beverages, or intake of caffeine and/or purine-rich foods or beverages (e.g. coffee, tea, chocolate, caffeinated carbonated beverages, cola, etc.) within 48 hours prior to screening, or refusal to stop drinking tea, coffee and/or caffeinated beverages during the trial.
  30. Performing or unwilling to refrain from strenuous physical activity, which could cause muscle aches or injury, including contact sports, at any time from 3 days prior to dosing through the end-of- study visit.
  31. Subjects who were compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical disease (e.g., infectious disease).
  32. Any condition or situation that, in the opinion of the investigator, would prevent proper evaluation of the safety or efficacy of the study drug according to the study protocol (e.g., poorly compliant subject, poorly vascular condition, allergies to medical plastics/latex).
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    HSK3486( study drug)

    One time, 0.4 mg/kg, IV bolus administration for 30 (±5) seconds

    Drug: HSK3486

  • Placebo comparator
    Placebo

    One time, IV bolus administration for 30 (±5) seconds

    Drug: Placebo

  • Active comparator
    Moxifloxacin hydrochloride

    One time, 0.4 g oral administration with 240 mL of warm water on an empty stomach.

    Drug: Moxifloxacin Hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Change-from-baseline in QTc Interval

    Corrected for HR using the individual QT correction method (QTcI) - ΔQTcI

    Time frame: From the base line ECG (D-2) to end of the period, up to 24 hours post-dose

07

Results

Posted Jan 13, 2026

Participant flow

A total of 175 subjects were screened in this study, 112 subjects failed screening, 3 subjects did not complete all procedures or assessments for inclusion and exclusion criteria, 48 subjects were randomized, and all 48 subjects completed the study.

Participant flow — Overall Study
MilestoneSequence 1: C-B-ASequence 2: A-B-CSequence 3: B-C-ASequence 4: C-A-BSequence 5: A-C-BSequence 6: B-A-C
Started888888
Completed888888
Not completed000000

Outcome measures

PrimaryChange-from-baseline in QTc Interval

Corrected for HR using the individual QT correction method (QTcI) - ΔQTcI

Time frame:
From the base line ECG (D-2) to end of the period, up to 24 hours post-dose
Reported as:
Least squares mean · ms
Change-from-baseline in QTc Interval
msC (Study Drug)B (Positive Control)A (Placebo)
30s post-dose2.1 (0.46 to 3.74)5.1 (2.96 to 7.29)-0.1 (-1.70 to 1.41)
1 min post-dose4.1 (2.07 to 6.12)-4.4 (-6.46 to -2.42)0.0 (-1.89 to 1.96)
2 min post-dose-3.1 (-4.24 to -1.90)-7.7 (-8.88 to -6.56)-3.1 (-4.24 to -1.91)
3 min post-dose-0.1 (-1.24 to 0.97)-4.4 (-5.51 to -3.33)-0.9 (-2.02 to 0.15)
5 min post-dose4.4 (3.33 to 5.46)-3.0 (-4.05 to -1.93)0.4 (-0.70 to 1.41)
8 min post-dose5.1 (3.97 to 6.23)-1.3 (-2.42 to -0.19)1.0 (-0.13 to 2.11)
10 min post-dose4.7 (3.51 to 5.82)-2.9 (-4.06 to -1.78)0.8 (-0.30 to 1.99)
15 min post-dose3.3 (2.33 to 4.26)-3.7 (-4.63 to -2.72)0.6 (-0.33 to 1.59)
30 min post-dose1.0 (0.16 to 1.82)-1.6 (-2.40 to -0.76)0.4 (-0.38 to 1.25)
1 h post-dose-0.1 (-1.22 to 1.12)5.2 (4.06 to 6.38)0.5 (-0.62 to 1.70)
2 h post-dose1.1 (-0.07 to 2.34)10.0 (8.80 to 11.20)1.3 (0.08 to 2.46)
3h post-dose0.5 (-0.75 to 1.77)13.2 (11.99 to 14.50)0.9 (-0.38 to 2.11)
4h post-dose2.6 (1.30 to 3.84)14.8 (13.55 to 16.09)3.0 (1.75 to 4.27)
6h post-dose-1.0 (-2.98 to 0.93)8.0 (6.10 to 9.97)-0.9 (-2.86 to 1.03)
8h post-dose-1.7 (-3.58 to 0.17)7.4 (5.58 to 9.29)1.12 (-2.41 to 1.30)
12h post-dose-0.9 (-2.70 to 0.91)6.2 (4.36 to 7.95)0.8 (-1.03 to 2.55)
24h post-dose-0.7 (-2.18 to 0.72)7.3 (5.85 to 8.74)0.1 (-1.35 to 1.52)
Statistical analysis
  • C (Study Drug) vs A (Placebo) · Mixed Models Analysis · p = <0.05 · Mean difference (final values): 4.10 · 90% CI 1.29 to 6.82Upper boundary is 6.82ms, does not cross margin of the 10ms
  • B (Positive Control) vs A (Placebo) · Mixed Models Analysis · p = <0.05 · Mean difference (final values): 12.4 · 90% CI 10.66 to 14.10Upper boundary is 14.10ms, cross margin of the 10ms
  • B (Positive Control) vs A (Placebo) · Mixed Models Analysis · p = <0.05 · Mean difference (final values): 11.8 · 90% CI 10.07 to 13.55Upper boundary is 13.55ms, cross margin of the 10ms

Adverse events

Collected over From Screen period ( day -21) to 7±1 day after the last dose. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HSK3486( Study Drug)0/48 (0%)0/48 (0%)3/48 (6.3%)
Placebo0/48 (0%)0/48 (0%)0/48 (0%)
Moxifloxacin Hydrochloride0/48 (0%)0/48 (0%)3/48 (6.3%)
Most frequent other events
Most frequent other events
EventHSK3486( Study Drug)PlaceboMoxifloxacin Hydrochloride
Neutrophil count decreasedInvestigations2/480/481/48
Alanine aminotransferase increasedInvestigations1/480/480/48
White blood cell counts decreasedInvestigations1/480/480/48
NauseaGastrointestinal disorders0/480/481/48
HeadacheNervous system disorders0/480/481/48
Blood creatine phosphokinase increasedInvestigations0/480/481/48
Blood thyroid stimulating hormone decreasedInvestigations0/480/481/48

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Sequence 1: C-B-ASequence 2: A-B-CSequence 3: B-C-ASequence 4: C-A-BSequence 5: A-C-BSequence 6: B-A-CTotal
Age (Years)34.3 ± 4.7731.1 ± 4.9430.9 ± 3.5631.0 ± 5.7631.6 ± 5.2634.9 ± 5.0032.3 ± 4.94
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1: C-B-ASequence 2: A-B-CSequence 3: B-C-ASequence 4: C-A-BSequence 5: A-C-BSequence 6: B-A-CTotal
Female2211028
Male66778640
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sequence 1: C-B-ASequence 2: A-B-CSequence 3: B-C-ASequence 4: C-A-BSequence 5: A-C-BSequence 6: B-A-CTotal
American Indian or Alaska Native0000000
Asian88888848
Native Hawaiian or Other Pacific Islander0000000
Black or African American0000000
White0000000
More than one race0000000
Unknown or Not Reported0000000
Baseline BMI
Baseline BMI(kg/m2)Sequence 1: C-B-ASequence 2: A-B-CSequence 3: B-C-ASequence 4: C-A-BSequence 5: A-C-BSequence 6: B-A-CTotal
Mean22.74 ± 0.96422.81 ± 2.01722.88 ± 1.42921.41 ± 0.77723.58 ± 1.29622.70 ± 1.977722.69 ± 1.546
08

Study locations

1 site
  • Beijing Gobroad Boren Hospital
    Beijing, China
09

References and documents

Publications

  • Kleiman R, Rudo T, Daley W, Hu M, Yan P, Zhou R, Hou J. Effects of Cipepofol on Cardiac Depolarization and Repolarization in Healthy Subjects: A Single-Center, Randomized, Placebo and Positive-Controlled Thorough QT Study. Drug Des Devel Ther. 2026 Jan 14;20:565051. doi: 10.2147/DDDT.S565051. eCollection 2026. PubMed 41858914 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2024 to primary completion in May 2024, 1 month.

Results were first posted in Jan 2026, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2025
First posted
Jan 27, 2025
StartActual
Apr 9, 2024
Primary completionActual
May 19, 2024
CompletionActual
Nov 26, 2024
Results first posted
Jan 13, 2026
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06795204
Responsible party
Sponsor
First posted
Jan 27, 2025
Start date
Apr 9, 2024
Primary completion
May 19, 2024
Completion
Nov 26, 2024
Results posted
Jan 13, 2026
Last update
Jan 13, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ciprofol

Start the discussion